Clinical trial
Vaccine Therapy in Treating Patients With Metastatic Cancer
NCT00021164 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00021164 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Metastatic Cancer |
| Official title | Immunization of HLA-A*0201 Patients With Metastatic Cancer Using a Peptide Epitope From the Telomerase Antigen |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological |
| Interventions | aldesleukin, incomplete Freund's adjuvant, telomerase: 540-548 peptide vaccine |
| Start date | May 1, 2001 |
| Completion | May 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: